Evidence at a glance
Human clinical evidence 1 of 3 (limited), preclinical evidence 2 of 3 (moderate).
My read of the published evidence, not a rating of whether it works. Preclinical findings cannot establish human benefit.
What is CJC-1295?
CJC-1295 is a modified fragment of growth hormone-releasing hormone, engineered in the 2000s by the Canadian company ConjuChem to solve GHRH's fatal flaw as a drug: a half-life measured in minutes. Its signature feature is a reactive group called a Drug Affinity Complex (DAC) that covalently bonds the peptide to albumin in the bloodstream, stretching its action from minutes to days.
ConjuChem's clinical programme did not survive; corporate development wound down without the compound ever approaching approval. What survived was the molecule itself, which migrated into the grey-market peptide economy. It is often sold, confusingly, both with and without the DAC modification under the same name. Those are meaningfully different molecules.
Why researchers are interested
The pituitary releases growth hormone in pulses, mostly at night, orchestrated by GHRH and its counterweight somatostatin. CJC-1295 binds the GHRH receptor on pituitary cells and, thanks to its albumin tether, keeps signalling for days rather than minutes. Early human pharmacology showed it could raise growth hormone and IGF-1 levels for a week or more after a single dose.
That persistence is scientifically interesting and physiologically double-edged. Natural GH secretion is pulsatile for a reason, and a constant elevation of the GHRH signal is a departure from the biology it imitates. Whether smoothing out those pulses matters over the long run is precisely the kind of question a completed drug programme would have answered. This one never completed.
| Sermorelin | Tesamorelin | CJC-1295 | Ipamorelin | |
|---|---|---|---|---|
| What it is | GHRH fragment (1 to 29) | Stabilized GHRH analogue | Long-acting GHRH analogue that binds albumin | Ghrelin-receptor agonist |
| Acts on | GHRH receptor | GHRH receptor | GHRH receptor | Ghrelin receptor (GHS-R1a) |
| Regulatory status | Original approved product discontinued; compounded in the US; no Canadian product | Approved in the US, and previously in Canada, for HIV-associated lipodystrophy only | Never authorized; development discontinued | Never authorized; development discontinued |
| Human evidence | Pediatric GH-deficiency trials, dated | Two Phase 3 trials in HIV lipodystrophy | Early-phase pharmacology studies only | Small volunteer studies; one failed ileus trial |
Regulatory status
CJC-1295 is not an authorized drug anywhere. No product containing it has been approved by Health Canada, the FDA, or any comparable regulator, and its clinical development ended without a submission. Everything sold under this name today is an unauthorized product, whatever the label says about research use.
What human research shows
The human record on CJC-1295 consists of early-phase pharmacology studies from the ConjuChem era: small trials in healthy adults showing sustained increases in growth hormone and IGF-1 after single or repeated doses. These were dose-finding and safety studies measured in weeks, with dozens of participants. The kind of work that precedes real efficacy trials.
Those efficacy trials never happened. There are no randomized studies showing CJC-1295 improves body composition, recovery, sleep, aging markers, or any health outcome in humans. A documented rise in a hormone level is a mechanism, not a benefit; plenty of compounds move biomarkers without helping the person attached to them.
What early research shows
Animal work on CJC-1295 established the expected upstream effects, elevated GH and IGF-1 and growth acceleration in some models, consistent with sustained GHRH receptor activation. It offers no reassurance on the questions that matter for chronic human use, and the broader animal literature complicates the sales pitch: chronically elevated growth hormone signalling is associated with *shorter* lifespan in several mouse models. Preclinical data cannot establish human benefit, and here it does not even point uniformly in the compound's favour.
What it's being studied for
Formal development of CJC-1295 is dormant, so the live research questions are mostly generic to GHRH biology. Researchers have investigated or are investigating:
- Sustained stimulation of growth hormone and IGF-1 secretion
- Pharmacokinetics of albumin-bound peptide drugs
- Body-composition effects of GHRH analogues as a class
- Growth hormone pulsatility and sleep architecture
- Age-related decline in the GH/IGF-1 axis
What remains uncertain
For CJC-1295, nearly everything past the hormone assay: long-term safety, cancer-risk implications of sustained IGF-1 elevation, effects on glucose metabolism, appropriate dosing in any population, and whether any functional benefit exists at all. The abandoned development programme means these questions have no institutional path to an answer.
Grey-market ambiguity adds a layer unique to this compound: with and without DAC versions circulating under one name, a buyer often cannot know which molecule, if either, is in the vial.
What people report
Online, CJC-1295 is almost always described in combination, typically alongside ipamorelin, with users crediting the pair for deeper sleep, faster recovery, and gradual leaning-out. Combination use makes attribution impossible even before the usual confounders arrive: concurrent training blocks, protein-focused diets, and the strong expectations of people who have invested money and needles in a protocol.
Vivid sleep is the most commonly repeated anecdote. It is also among the easiest effects to produce by expectation alone. Without controlled human data, these stories are testable hypotheses. Nothing more.
Sources
- Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GHRH. Journal of Clinical Endocrinology and Metabolism, 2006.
